Publikationen Prof. Dr. med. Rainer Wessely
1. Sautter BM, Wessely R, Bihl H. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 1993;169:595-600.
2. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol. 1996;70:7811-8.
3. Schwarz EM, Badorff C, Hiura TS, Wessely R, Badorff A, Verma IM, Knowlton KU. NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J Virol. 1998;72:5654-60.
4. Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation. 1998;98:450-457.
5. Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, Kandolf R, Knowlton KU. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest. 1998;102:1444-53.
6. Wessely R, Klingel K, Knowlton KU, Kandolf R. Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling : Implications for Mortality and Early Viral Replication. Circulation. 2001;103:756-761.
7. Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandl R, Murr A, Klein CA, Baeuerle PA. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol Cell. 2001;7:1059-69.
8. Wessely R, Hengst L, Jaschke B, Wegener F, Richter T, Lupetti R, Paschalidis M, Schomig A, Brandl R, Neumann FJ. A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Gen. 2003;12:177-187.
9. Wessely R, Fateh-Moghadam S, Bocksch W, Jager G, Hetzer R, Gawaz M. Cytomegalovirus Infection Predicts Progression of Heart Transplant Vasculopathy. Transplantation. 2003;76:1470-1474.
10. Wessely R. Coxsackieviral replication and pathogenicity: lessons from gene modified animal models. Med Microbiol Immunol. 2004, 193(2-3):71-74
11. Wessely R, Paschalidis M, Wagenpfeil S, Wegener F, Neumann FJ, Theiss W. A comprehensive approach to visual and functional assessment of experimental vascular lesions in vivo. Am J Physiol Heart Circ Physiol. 2004; 286(6):H2461-2467.
12. Jaschke B, Milz S, Wegener F., Schömig A, Kastrati A, Wessely R. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: implications for the applicability on drug eluting stents to prevent neointima formation following vascular injury. FASEB J. 2004;18(11):1285-1287
13. Wessely R, Fateh-Moghadam S, Jaeger G, Bocksch W, Hetzer R, Gawaz M. Cytomegalovirus and progressing heart transplant vasculopathy: enough evidence that needs to be translated in appropriate screening and treatment regimens. Transplantation. 2004;78:632-633
14. Wessely R, Vorpahl M, Schömig A, Klingel K. Late constrictive involvement of the pericardium in a case of previous myocarditis. Cardiovasc Pathol. 2004;13:327-329.
15. Wessely R, Seidl S, Schömig A. Cardiac involvement in Emery-Dreifuss muscular dystrophy. Clin Genet. 2005;67:220-223.
16. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stöver M, Wintermantel E, Kastrati A, Schömig A. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005; 25:748-753.
17. Merl S, Michaelis C, Jaschke B, Vorpahl M, Seidl S, Wessely R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation. 2005;111:1583-1592
18. Wessely R. Interference by interferons: Janus faces in vascular proliferative diseases. Cardiovascular Res 2005;66:433-443
19. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schomig A. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26(15):1475-81
20. Ott I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, Zohlnhofer D, Wessely R, Rudelius M, Schomig A, Carmeliet P. Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor. Circ Res. 2005;97(3):293-8.
21. Fröhlich G, Porner M, Wessely R. Aortic coarctation visualized by 16-row detector multislice computed tomography. Circulation. 2005;112(6):e81.
22. Wessely R, Pache J, Schomig A. Recurrence of in-stent restenosis in cardiac allograft vasculopathy following implantation of a sirolimus-eluting stent. Transpl Int. 2005;18(9):1113-5.
23. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353(7):663-70.
24. Wessely R, Kastrati A, Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143(5):392-4.
25. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68(3):483-92.
26. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? Circulation. 2005;112(18):2759-61.
27. Wessely R. Paclitaxel-eluting stents with erodable polymer appear safe. Commentary. Evid Based Cardiovasc Med. 2005;9(4):297-300.
28. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A; Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113(2):273-9.
29. Wessely R, Schomig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47(4):708-14.
30. Wessely R, Bradaric C, Seybold S. Ruptured vulnerable coronary plaque and Tc-99m sestamibi-based assessment of infarct size. Clin Nucl Med. 2006;31(6):331-2.
31. Stöver M, Renke-Gluszko M, Schratzenstaller T, Will J, Klink N, Behnisch B, Kastrati A, Wessely R, Hausleiter J, A. S, Wintermantel E. Microstructuring of stainless steel implants by electrochemical etching. J Mater Sci. 2006;41:5569-5575.
32. Wessely R, Augustin N. Porner M, Schomig A, Lange R. Giant coronary aneurysm obstructing the right heart. Lancet. 2006 Jul 29;368(9533):386.
33. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schomig A, Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48(7):1304-9.
34. Xiong D, Yajima T, Lim BK, Stenbit A, Dublin A, Dalton ND, Summers-Torres D, Molkentin JD, Duplain H, Wessely R, Chen J, Knowlton KU. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007;115:94-102.
35. Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A, Blaich B, Iijima R, Pache J, Kastrati A, Schömig A. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol. 2007;49;1265-71
36. Merl S, Wessely R. Anti-coxsackieviral efficacy of RNA interference is highly dependent on genomic target selection and emergence of escape mutants. Oligonucleotides. 2007;17:44-53
37. Wessely R, Blaich B, BelAiba RS, Merl S, Görlach A, Kastrati A, Schömig A. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus: implications for local drug delivery. Thromb Haemost. 2007; 97:1003-12
38. Wessely R, Botnar RM, Vorpahl M, Schwaiger M, Schömig A, Ibrahim T. Subacute thrombotic occlusion and spontaneous recanalization of the right coronary artery following PCI for STEMI visualized by coronary angiography and cardiac MRI. Circulation 2007;116:e78-80
39. Schulz C, Kress W, Schömig A, Wessely R. Endocardial cushion defect in a patient with Crouzon syndrome carrying a mutation in the fibroblast growth factor receptor (FGFR)-2 gene. Clin Genet. 2007;72:305-7
40. Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J. 2007;28:2720-5
41. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R, Schömig A, Kastrati A; for the Intracoronary Stenting and Angiographic Restenosis Investigators – Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating Strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J. 2008;29(16):1975-82.
42. John MC, Wessely R, Kastrati A, Schömig A, Joner M, Uchihashi M, Crimins J, Listhrop RA, Kolodgie F, Gold HK, Virmani R, Finn A. Differential healing response in polymer vs. non-polymer based sirolimus eluting stents. JACC Cardiovasc Interv, 2008;1:535-544
43. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R, Vogeser M, Hausleiter J, Joner M, Schömig A, Wessely R. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials, 2009;30(4):632-7
44. Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A for the COntrast media and NephroToxicity following coronary Revascularization by AngioplaSTy (CONTRAST) trial investigators. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv, 2009;5:430-7
45. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol, 2010;4:194-203
46. Wessely R., Reddan D. Contrast media, cardiovascular interventions and kidney injury: does contrast osmolarity matter? Eur Nephrol, 2010;4:62-67
47. Wessely R. Atherosclerosis and cell cycle – put the brakes on! Critical role for cyclin-dependent kinase inhibitors. J Am Coll Cardiol, 2010;55:2269-71
48. Merl S., Wessely R. RNA interference to treat enteroviral disease: current status and clinical perspectives. Curr Mol Ther, 2010;10:550-64
49. Wessely R. Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy due to urgent surgery. Am J Ther, 2011:280-282
50. Poll LW, Sadra B, Rühlow S, Wessely R. Thrombosis of a large saphenous vein graft aneurysm leading to acute myocardial infarction 21 years after coronary artery bypass grafting: role of cardiac multi-slice computed tomography. Interact Cardiovasc Thorax Surg 2011:284-286
51. Wessely R, Andres V. Limus is not limus– a proposal to adjust terminology in the context of drug-eluting stents. J Cardiovasc Pharmacol 2012;59:485-86
52. Tolg R, Zeymer U, Birkemeyer R, Wessely R, Eggebrecht H, Bocksch W, Schneider S, Richardt G, Hamm C. Cardiogoniometry as a diagnostic tool in patients with acute coronary syndromes. Results of the CGM@ACS trial. Clin Res Cardiol 2012;101:727-36
53. Birkemeyer R, Toelg R, Zeymer U, Wessely R, Jäckle S, Hairedini B, Lübke M, Assfalg M, Jung W. Comparison of Cardiogoniometry and electrocardiography with perfusion cardiac magnetic resonance imaging and late gadolinium enhancement. Europace 2012;14:1793-8
54. Wessely R. Cardiogoniometry – an evolving, simple-to-use technology for detection of underlying cardiovascular disease in patients presenting with acute chest pain. Hosp Healtcare Eur, 2013.
55. Foerst J, Vorpahl M, Engelhardt M, Koehler T, Tiroch K, Wessely R. Evolution of coronarx stents: from bare metal-stents to fully biodegradable drug-eluting stents. Comb Prod Ther 2013; epub ahead of print
56. Wessely R, Marzocchi A, Schwacke H, Bertel O, Laanmets P, Perisic Z, Toelg R, Jagic N, Elsässer A, Danzi GB.Wessely R, Paunovic D. Long-term follow-up of coronary venous bypass graft lesions treated with a new generation DES with bioabsorbable polymer. J Interv Cardiol 2013;26:425-33
57. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P; EUROMAX Investigators.
Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17
58. Vorpahl M, Schönhofer-Merl S, Michaelis C, Flotho A, Melchior F, Wessely R.
The Ran GTPase-Activating Protein (RanGAP1) Is Critically Involved in Smooth Muscle Cell Differentiation, Proliferation and Migration following Vascular Injury: Implications for Neointima Formation and Restenosis. PLoS One 2014;9: e101519
59. De Francesco M, Ronco C, Wacinski PJ, Wessely R, Hernandez F, Lamotte M
Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland and Spain.
J Med Econ 2015 (Epub ahead of print)
60. Wessely R, Amoroso G
Self-expanding coronary stents: rationale, clinical status, future prospects
EMJ Cardiol 2015 (Epub ahead of print)
